DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products and APT Pharmaceuticals, Inc. announced today they have signed a manufacturing agreement. DSM will produce the commercial drug supply as a sterile product for pulmonary delivery for APT Pharmaceuticals. The agreement will utilize DSM’s commercial facilities in Greenville, North Carolina.
“DSM has a superior reputation in sterile manufacturing, experience with similar drug products, and an excellent working relationship with the FDA.” commented Howard Raff, PhD, COO APT Pharmaceuticals, Inc., “In addition to their experience; they also have the capability to provide increased scale through commercialization.”
“DSM Pharmaceuticals Inc. is pleased to welcome APT as a client. APT is a specialty drug development company with an outstanding staff that is focused on effective treatments for significant unmet medical needs and we at DSM are proud to be part of those efforts.” stated Terry Novak, President, DSM Pharmaceuticals Inc.
About APT Pharmaceuticals, Inc. APT Pharmaceuticals, a specialty drug development company primarily focused on inhaled treatments for serious lung diseases, is based in Burlingame, California. APT is backed by several leading health care investors including Vivo Ventures, Versant Ventures, Great Point Partners and Charter Life Sciences. For more information, please visit www.aptbio.com
About DSM Pharmaceuticals Inc. DSM Pharmaceuticals, Inc. a business unit of DSM Pharmaceutical Products, is a global provider of custom manufacturing services to the pharmaceutical and biopharmaceutical industries. Our breadth of manufacturing services include the areas of steriles, orals and topicals, including dose form manufacturing, scheduled drugs, clinical manufacturing, fill finish manufacturing, and lyophilization services.
About DSM DSM creates innovative products and services in Life Sciences and Materials Sciences, contributing to the quality of life. DSM’s products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and enjoyable way of living. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics & electronics, life protection and housing. The company strategy, Vision 2010 – Building on Strengths, focuses on accelerating profitable and innovative growth of the company’s specialties portfolio.
For further information please contact: DSM Pharmaceutical Products Terry Novak President Business Unit Director DSM Pharmaceuticals Inc. +1-973-257-8471 Terry.Novak@dsm.com
